Navigation Links
Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Date:12/17/2007

VANCOUVER, Dec. 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its innovative, anti-infective 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC).

"We are pleased to complete the submission of a 510(k) application to the FDA for our 5-FU CVC, as we believe this represents another important step towards commercializing this product line and developing our 5-FU anti-infective platform," said Dr. William Hunter, President and CEO of Angiotech.

Pending the receipt of all necessary regulatory approvals, Angiotech anticipates launching the commercial 5-FU CVC product line in 2008.

About Central Venous Catheters (CVC) and Catheter-Related Infections

Central venous catheters (CVC) are usually inserted into critically ill patients for extended periods of time to administer fluids, drugs, and nutrition, as well as facilitate frequent blood draws. One of the complications associated with CVC implantation is infection, which can occur when bacteria contaminate the catheter. CVC infections that progress to bloodstream infections, or septicemia, can become life threatening. In the U.S., the cost per catheter-related infection can range from $3,700 to $29,000(1). In addition, the Centers for Disease Control and Prevention (CDC) has raised concerns about the overuse of traditional antibiotics, which can contribute to an increase in the antibiotic resistance of bacteria.

About Angiotech's 5-FU CVC

Angiotech believes that 5-FU, a well-known and approved compound, has the potential to be used as a coat
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized ... The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Costello served as ... system to protect the Orange County, Texas area from future storm surge flooding, ... team in determining several potential levee alignment alternatives for providing protection, Costello also balanced ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... company is making good progress in evaluating the full range of capabilities of ... cells. Adult tissue stem cells perform the day-to-day renewal and repair of normal ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... ("Angiotech") (NASDAQ: ANPI , TSX: ANP), a ... the commencement,of a cash tender offer of the ... that will result in an aggregate purchase price ... Premiums" listed in the,table below) of $165 million ...
... Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty,biopharmaceutical company, will ... Results press release will be issued at: ... Investor meeting and conference call time: 14:30 BST ... conference call:, Angus Russell, Chief Executive Officer, Graham ...
... BIOCITECH, France, July 3 Cellectis SA today,announced ... over the use of Cellectis, patents covering certain ... human therapies, including,the development of fully human monoclonal ... an upfront of 12,450,000$ from Regeneron.,In addition, Regeneron ...
Cached Biology Technology:Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 2Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 3Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 4Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 5Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 6Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 7Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 8Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology 2
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... deformity that cases a depression in the chest wall inhibits ... of 327 patients published in the Journal of Pediatrics ... anecdotally, that children with more severe pectus excavatum report more ... exercise intolerance," said one of the study,s lead authors, Dr. ...
... are common during the year following a traumatic brain injury ... tend to occur more often among females and those with ... Journal of Neurotrauma , a peer-reviewed journal published by ... at www.liebertpub.com/neu More than 70% of patients ...
... have been working for years to nail down the ... hormones, called brassinosteroids, send from a protein on the ... New research from Carnegie scientists Tae-Wuk Kim and Zhiyong ... Francisco, isolated another link in this chain. Fully understanding ...
Cached Biology News:New component of a plant steroid-activated pathway discovered 2
Roll of Mesh 5m x 25cm...
... Innovative HL-2000 HybriLinker combines the benefits of a ... self-contained, space saving unit. , ... Laboratory allows crosslinking ,and hybridization at one location ... HL-2000 operate independently of each other , ...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
... Lambda Protein Phosphatase ( ... protein phosphatase with activity ... and tyrosine residues. It ... product of the ORF221 ...
Biology Products: